Venatorx Pharmaceuticals
Clinical-stage biopharmaceutical company focused on developing novel anti-infective agents to address the growing threat of antimicrobial resistance, particularly drug-resistant bacterial infections.
Notes
Venatorx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel anti-infective agents to address the growing threat of antimicrobial resistance. The company is headquartered in Malvern, Pennsylvania.
The company is developing antibiotics and other anti-infective agents to treat drug-resistant bacterial infections, which represent a significant and growing public health threat. Venatorx's pipeline includes novel beta-lactamase inhibitors and other mechanisms to overcome bacterial resistance.
The company is part of the Abingworth portfolio.
Team
- Christopher Burns, Ph.D. - Founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/christopherburns
Additional Research Findings
- Part of Abingworth portfolio
- Anti-infective drug development
- Antimicrobial resistance focus
- Beta-lactamase inhibitor programs
- Malvern, Pennsylvania headquarters
- Founded in 2010
- Clinical-stage company
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |